Description

• General description: Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Nitisinone is a medication, effectively used for the treatment and maintainence of alkaptonuria, an autosomal recessive disease. Its mode of action involves the inhibition of second enzyme in the tyrosine pathway, 4-hydroxyphenylpyruvate dioxygenase that produces HGA from 4-hydroxyphenylpyruvate.[1][2]
• Application: Nitisinone may be used as a pharmaceutical reference standard for the quantification of the analyte in phamraceutical formulations using high-performance liquid chromatography technique.[3]
• Biochem/physiol Actions: Nitisinone is a competitive inhibitor that reversibly inhibits 4-Hydroxyphenylpyruvate oxidase (dioxygenase). Nitisinone is used in the treatment of hereditary tyrosinemia type 1, where it blocks the degradation of tyrosine into harmful substances.
• Analysis Note: These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
• Other Notes: This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
• Footnote: To see an example of a Certificate of Analysis for this material enter LRAC0575 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.